高苒课题组
高苒课题组成立于2014年，实验室面积约100平方米，拥有倒置荧光显微镜、生物安全柜、细胞培养箱、分析天平、PCR仪、超声破碎仪、流式细胞仪等细胞与分子生物学常用设备。研究所平台提供激光共聚焦显微镜以及小动物PET/CT、7T小动物核磁共振（MRI）、小动物超声成像、小动物活体光学成像等最为先进的小动物专用高分辨率分子影像设备，能较好的满足肿瘤研究相关细胞、分子生物学、动物实验的需求。
高苒课题组的研究方向是肿瘤动物模型创制，并以动物模型为基础进行肿瘤的比较医学研究。研究团队以肿瘤动物模型创制为主体，充分借助研究所具有的优势平台和资源，针对肿瘤动物模型创制，开展原创性、前沿性和系统性研究。课题组在研究过程中强调互助协作、资源共享，提倡交叉学科的融合，利用肿瘤动物模型揭示肿瘤发生、发展的机制，并且为肿瘤治疗及抗癌药物研发提供有力工具。
| 课题组负责人： | ||
 |
||
| 高苒 副研究员 |
||
| 组员： | ||
 |
 |
 |
| 张文龙 助理研究员 |
李梦媛 主管技师 |
杨星九 技师 |
联系方式：010-67779532
科研成果：
目前课题组拥有人源性肿瘤异种移植模型（PDX）、皮下/原位移植性肿瘤小鼠模型，脑转移瘤、肺转移瘤小鼠模型，应用双光子显微镜成像技术构建的小鼠脑转移瘤活体成像模型等300余种，并且能够利用肿瘤动物模型进行抗癌药物的筛选及药效学评价，以及进行相关的细胞生物学与分子生物学检测。
1.Cao L, Huang T, Chen X, Li W, Yang X, Zhang W, Li M, Gao R*.Uncovering the interplay between pH receptors and immune cells: Potential drug targets (Review). Oncol Rep. 2021 Oct;46(4):228. doi: 10.3892/or.2021.8179. Epub 2021 Sep 3.
2.Cao L, Li W, Yang X, Zhang W, Li M, Zhang H, Qin C, Chen X*, Gao R*. Inhibition of host Ogr1 enhances effector CD8+ T-cell function by modulating acidic microenvironment. Cancer Gene Ther. 2021 Jun 22. doi: 10.1038/s41417-021-00354-0. Epub ahead of print.
3.Li W, Cao L, Li M, Yang X, Zhang W, Song Z, Wang X, Zhang L, Morahan G, Qin C*, Gao R*. Novel spontaneous myelodysplastic syndrome mouse model. Animal Model Exp Med. 2021 May 14;4(2):169-180.
4.Li W, Li M, Yang X, Zhang W, Cao L, Gao R*. Summary of animal models of myelodysplastic syndrome. Animal Model Exp Med. 2021 Feb 3;4(1):71-76.
5.Zhang G, Yang X, Gao R*. Research progress on the structure and function of endomucin. Animal Model Exp Med. 2021 Jan 15;3(4):325-329. doi: 10.1002/ame2.12142.
6.Liu H, Chen X, Yang X, Li M, Zhang W, Zhang G, Zhan X, Cao L, Li W, Huang Z*, Gao R*. Involvement of the Wnt/β-Catenin signaling pathway in the heterogenous nuclear ribonucleoprotein K-driven inhibition of proliferation and migration in head and neck squamous cell carcinoma. Oncol Lett. 2020 Dec;20(6):394.
7.Shi X*, Gao K, Xiong S, Gao R*. Multifunctional Transferrin Encapsulated GdF3 Nanoparticles for Sentinel Lymph Node and Tumor Imaging. Bioconjug Chem. 2020 Nov 18;31(11):2576-2584.
8.Zhang W, Han Y, Li W, Cao L, Yan L, Qin C*, Gao R*. Clinical data analysis reveals the role of OGR1 (GPR68) in head and neck squamous cancer. Animal Model Exp Med. 2020 Mar 18;3(1):55-61.
9.Li M, Zhang W, Yang X, Liu H, Cao L, Li W, Wang L, Zhang G, Gao R*. Downregulation of HNRNPK in human cancer cells inhibits lung metastasis. Animal Model Exp Med. 2019 Nov 21;2(4):291-296.
10.Shi X, Gao K, Gao R*. 64Cu-Based Pretargeted Immuno-Positron Emission Tomography and Near-Infrared Fluorescence Imaging of the Vascular Endothelial Growth Factor. ACS Omega 2019, 4, 5310-5316.
11.Sun S, Li K, Lei Z, Xiao L, Gao R*, Zhang Z*. Immunomodulatory activity of polysaccharide from Helicteres angustifolia L. on 4T1 tumor-bearing mice. Biomed Pharmacother. 2018 May;101:881-888.
12.Shi X, Gao K, Huang H, Gao R*. Pretargeted Immuno-PET Based on Bioorthogonal Chemistry for Imaging EGFR Positive Colorectal Cancer. Bioconjug Chem. 2018 Feb 21;29(2):250-254.
13.Huang H, Han Y, Yang X, Li M, Zhu R, Hu J, Zhang X, Wei R, Li K, Gao R*. HNRNPK inhibits gastric cancer cell proliferation through p53/p21/CCND1 pathway. Oncotarget. 2017 Oct 17;8(61):103364-103374.
14.Wei R*, Li B, Guo J, Li M, Zhu R, Yang X, Gao R*. Smurf1 targets Securin for ubiquitin-dependent degradation and regulates the metaphase-to-anaphase transition. Cell Signal. 2017 Oct;38:60-66.
15.Wei R*, Guo J, Li M, Yang X, Zhu R, Huang H, Li K, Zhang L, Gao R*. Smurf1 controls S phase progression and tumorigenesis through Wee1 degradation. FEBS Lett. 2017 Apr;591(8):1150-1158
微信公众号
京公网安备11010502033649